ペンシルベニアにおける膠芽腫の臨床試験
ペンシルベニア内の拠点で、膠芽腫に関する21件の研究が参加者を募集しています。
ペンシルベニア内の都市
公式研究テキスト（英語）
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05432804A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT03970447Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
- Penn State Health Milton S. Hershey Medical Center, Hershey
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT05902169Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07326566A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia
被験者募集中第1/2相
25歳以下 · 全性別 · 2026/09/25更新 · NCT04094610Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- Allegheny Health Network, Pittsburgh
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07195591Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
- Hospital of the University of Pennsylvania, Philadelphia
- University of Pennsylvania, Philadelphia
被験者募集中早期第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06613841Targeted Pediatric High-Grade Glioma Therapy
- Children's Hospital of Philadelphia, Philadelphia
被験者募集中観察研究
12 Months – 39 Years · 全性別 · 2026/09/08更新 · NCT05839379Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06860594Study of Olutasidenib and Temozolomide in HGG
- Children's Hospital of Philadelphia, Philadelphia
被験者募集中第2相
12歳〜39歳 · 全性別 · 2026/09/01更新 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Thomas Jefferson University Hospital, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT05303519INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- University of Pittsburgh Medical Center, Pittsburgh
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT02977780WBSI Guided Personalized Delivery of TTFields
- Abramson Cancer Center, Philadelphia
- Penn Medicine, University of Pennsylvania, Philadelphia
被験者募集中
22歳以上 · 全性別 · 2026/08/06更新 · NCT05086497Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
- Penn State Milton S. Hershey Medical Center, Hershey
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/07/17更新 · NCT07225621DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
- UPMC Presbyterian Hospital, Pittsburgh
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/01更新 · NCT06805305Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Children's Hospital of Philadelphia, Philadelphia
被験者募集中早期第1相健康なボランティア歓迎
1歳〜21歳 · 全性別 · 2026/06/29更新 · NCT06333899ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- Children's Hospital of Philadelphia, Philadelphia
被験者募集中第1相
2歳〜21歳 · 全性別 · 2026/06/11更新 · NCT04732065Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- University of Pittsburg Medical Center (UPCM), Pittsburgh
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/11更新 · NCT05283330Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Children's Hospital of Philadelphia, Philadelphia
被験者募集中第2相
12 Months – 39 Years · 全性別 · 2026/05/29更新 · NCT05843253SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Philadelphia
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- Penn State Milton S. Hershey Medical Center, Hershey
被験者募集中第2相
18歳以上 · 全性別 · 2025/06/27更新 · NCT03175224ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。